BSE · 531210
Colinz Laboratories Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹7 Cr with net profit ₹0 Cr — a 7.28% net margin, versus 6.66% the period before.
Shareholding
As of 2026-06-30
- Promoter50.6%
- Public49.4%
3,174 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2.43× from low to high.
Risk flags
Derived from disclosed data
- Under exchange surveillance — ESM · ESM 1. Trading may carry price bands, periodic call auction or higher margins.
- Promoter holding fell 15.4 percentage points to 50.6% in the latest disclosure.
Peer comparison
Pharmaceuticals - Indian - Formulations · ranked #36 of 50 by market cap · medians across 41 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Torrent Pharmaceuticals Limited | ₹1,85,608 Cr | 84.69 | 22.07 | 25.49% | 15.55% |
| Ajanta Pharma Limited | ₹42,115 Cr | 157.89 | 9.33 | 23.33% | 19.37% |
| Gland Pharma Limited | ₹41,522 Cr | 113.08 | 4 | 9.92% | 15.98% |
| Rubicon Research Limited | ₹25,126 Cr | 325.88 | 19.54 | 19.14% | 14.07% |
| Caplin Point Laboratories Ltd. | ₹19,725 Cr | 115.95 | 5.5 | 17.88% | 29.32% |
| Eris Lifesciences Limited | ₹19,627 Cr | 68.76 | 5.03 | 15.87% | 19.89% |
| Shilpa Medicare Ltd. | ₹11,858 Cr | 110.04 | 4.58 | 9.39% | 15.81% |
| Marksans Pharma Limited | ₹11,794 Cr | 79.59 | 3.9 | 13.82% | 14.16% |
| Senores Pharmaceuticals Limited | ₹6,130 Cr | 167.21 | 6.57 | 12.36% | 18.32% |
| Bliss GVS Pharma Ltd. | ₹4,848 Cr | 141.97 | 4.05 | 8.95% | 11.15% |
| Colinz Laboratories Ltd.(this company) | ₹20 Cr | 19.31 | 1.13 | 5.12% | 8.31% |
AI analysis
AI-generated · google/gemini-2.5-flashColinz Laboratories Ltd. is listed on the Indian markets with a market capitalization of Rs 20 Cr. The company reported a revenue of Rs 6.83 Cr and an EPS of 4.08. The PE ratio stands at 19.6, and the book value is 69.7. The company's ROE is 5.12% and ROCE is 7.05%.
Positives
- +The company has a low debt-to-equity ratio of 0.07, indicating minimal reliance on borrowed funds.
- +Promoter shareholding is substantial at 50.5998% as of June 30, 2026.
- +No promoter shares are pledged, indicating financial stability and confidence from the promoters.
Negatives
- −Revenue declined from Rs 7.3046 Cr in Mar 2024 to Rs 6.8256 Cr in Mar 2025.
- −The company has a relatively low Return on Equity (ROE) of 5.12%.
- −Colinz Laboratories Ltd. is currently under ESM Stage 1 surveillance.
- −The company's dividend yield is 0, indicating no recent dividend payouts.
Financial Performance
Colinz Laboratories Ltd. has seen fluctuations in its annual financial performance. Revenue declined from Rs 7.3046 Cr in Mar 2024 to Rs 6.8256 Cr in Mar 2025. Net profit, however, increased from Rs 0.4867 Cr in Mar 2024 to Rs 0.4966 Cr in Mar 2025. Diluted EPS also rose slightly from 1.93 in Mar 2024 to 1.97 in Mar 2025.
Profitability & Returns
For the most recent fiscal year, Colinz Laboratories Ltd. reported a profit margin of 8.31%. The company's Return on Equity (ROE) was 5.12%, while the Return on Capital Employed (ROCE) stood at 7.05%. These figures indicate the efficiency with which the company utilizes equity and capital to generate profits.
Balance Sheet
The company maintains a low debt-to-equity ratio of 0.07, suggesting minimal reliance on borrowed capital. The book value per share is Rs 69.7. This indicates a healthy financial structure with a substantial proportion of assets funded by equity rather than debt.
Ownership & Pledges
As of June 30, 2026, the promoter holding in Colinz Laboratories Ltd. was 50.5998% and public shareholding was 49.4002%. There were no shares pledged by the promoters, indicating financial stability regarding promoter holdings. Neither DII nor FII held any shares.
Regulatory & Surveillance
Colinz Laboratories Ltd. is under the ESM (Enhanced Surveillance Measure) framework, specifically ESM Stage 1. This classification indicates that the stock is subject to certain surveillance measures, which may include additional disclosure requirements or trading restrictions.
Data as of — price: 2026-07-29 · financials: Mar 25 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.